Mirror Biologics, Inc., a leading biopharmaceutical company, recently appointed Elizabeth Adkins Czerepak as their new Chief Financial Officer (CFO) and Vice President of Corporate Development. With over 13 years of experience in the biotechnology industry, Ms. Czerepak has successfully led teams in launching public offerings and has extensive venture capital investment experience.
Dr. Michael Har-Noy, Founder and acting CEO of Mirror Biologics, expressed his enthusiasm for Ms. Czerepak joining the team, noting her valuable expertise in financial and strategic operations within the biotech and big pharma sectors. He highlighted her track record of creating value for investors and her experience in negotiating complex financial transactions, which will be beneficial as the company advances its clinical and manufacturing programs to late-stage development.
In response to her appointment, Elizabeth Czerepak shared her excitement about joining Mirror Biologics, praising the company’s innovation, top talent, and late-stage clinical assets. She emphasized the potential of the lead AlloStim® product candidate to transform cancer treatment and address infectious diseases, as well as potentially reversing the effects of aging on the immune system. Ms. Czerepak expressed her confidence in the company’s vision, expertise, and passion for improving patient outcomes through next-generation immunotherapy solutions.
Mirror Biologics, Inc. is a private corporation headquartered in Tampa, Florida, with manufacturing operations in Jerusalem, Israel, and clinical support hubs in Bangkok, Thailand, and Kuala Lumpur, Malaysia. The company specializes in developing therapeutic and prophylactic immunotherapy products using non-genetically altered “off-the-shelf” living immune cells. Clinical trials are currently underway for metastatic colorectal cancer, advanced/metastatic liver cancer, and immune system rejuvenation in healthy seniors.
With a focus on providing non-toxic and affordable immunotherapy treatments for patients with incurable diseases, Mirror Biologics is committed to making its innovative therapies widely accessible. The company’s mission is driven by a desire to improve patient outcomes and extend lives through cutting-edge immunotherapy solutions.
Overall, Elizabeth Adkins Czerepak’s appointment as CFO and Vice President of Corporate Development at Mirror Biologics, Inc. signals a significant step forward for the company as it continues to advance its groundbreaking research and development efforts in the biopharmaceutical industry.
Source link
